{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T04:32:53Z","timestamp":1761971573150,"version":"build-2065373602"},"reference-count":29,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":988,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast J"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1111\/tbj.12045","type":"journal-article","created":{"date-parts":[[2012,12,18]],"date-time":"2012-12-18T19:02:50Z","timestamp":1355857370000},"page":"10-21","source":"Crossref","is-referenced-by-count":20,"title":["Acceptability and Adherence in a Chemoprevention Trial among Women at Increased Risk for Breast Cancer Attending the Modena Familial Breast and Ovarian Cancer Center (Italy)"],"prefix":"10.1155","volume":"19","author":[{"given":"Elisabetta","family":"Razzaboni","sequence":"first","affiliation":[{"name":"Department of Oncology and Haematology; Hereditary Breast and Ovarian Cancer Center, University of Modena and Reggio Emilia; Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Toss","sequence":"additional","affiliation":[{"name":"Department of Oncology and Haematology; Hereditary Breast and Ovarian Cancer Center, University of Modena and Reggio Emilia; Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Cortesi","sequence":"additional","affiliation":[{"name":"Department of Oncology and Haematology; Hereditary Breast and Ovarian Cancer Center, University of Modena and Reggio Emilia; Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Marchi","sequence":"additional","affiliation":[{"name":"Department of Oncology and Haematology; Hereditary Breast and Ovarian Cancer Center, University of Modena and Reggio Emilia; Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Sebastiani","sequence":"additional","affiliation":[{"name":"Department of Oncology and Haematology; Hereditary Breast and Ovarian Cancer Center, University of Modena and Reggio Emilia; Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"De Matteis","sequence":"additional","affiliation":[{"name":"Department of Oncology and Haematology; Hereditary Breast and Ovarian Cancer Center, University of Modena and Reggio Emilia; Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Federico","sequence":"additional","affiliation":[{"name":"Department of Oncology and Haematology; Hereditary Breast and Ovarian Cancer Center, University of Modena and Reggio Emilia; Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,12,17]]},"reference":[{"key":"10.1111\/tbj.12045-BIB0001|tbj12045-cit-0001","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","article-title":"Global Cancer Statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"10.1111\/tbj.12045-BIB0002|tbj12045-cit-0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1023\/A:1006484604454","article-title":"Chemoprevention of breast cancer","volume":"62","author":"Brown","year":"2000","journal-title":"Breast Cancer Res Treat"},{"key":"10.1111\/tbj.12045-BIB0003|tbj12045-cit-0003","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/tbj.12045-BIB0004|tbj12045-cit-0004","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","article-title":"Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of tamoxifen and raloxifene (STAR) P-2 Trial","volume":"295","author":"Vogel","year":"2006","journal-title":"JAMA"},{"key":"10.1111\/tbj.12045-BIB0005|tbj12045-cit-0005","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1158\/1940-6207.CAPR-10-0076","article-title":"Update of the NSABP Study of tamoxifen and raloxifene (STAR) P-2 Trial: preventing breast cancer","volume":"3","author":"Vogel","year":"2010","journal-title":"Cancer Prev Res"},{"key":"10.1111\/tbj.12045-BIB0006|tbj12045-cit-0006","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0140-6736(98)05071-5","article-title":"Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial","volume":"352","author":"Powles","year":"1998","journal-title":"Lancet"},{"key":"10.1111\/tbj.12045-BIB0007|tbj12045-cit-0007","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0140-6736(98)85011-3","article-title":"Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hysterectomised women. Italian Tamoxifen Prevention Study","volume":"352","author":"Veronesi","year":"1998","journal-title":"Lancet"},{"key":"10.1111\/tbj.12045-BIB0008|tbj12045-cit-0008","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(02)09962-2","article-title":"First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial","volume":"360","author":"Cuzick","year":"2002","journal-title":"Lancet"},{"key":"10.1111\/tbj.12045-BIB0009|tbj12045-cit-0009","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","article-title":"The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation","volume":"281","author":"Cummings","year":"1999","journal-title":"JAMA"},{"key":"10.1111\/tbj.12045-BIB0010|tbj12045-cit-0010","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0140-6736(03)12342-2","article-title":"Overview of the main outcomes in breast-cancer prevention trials","volume":"361","author":"Cuzick","year":"2003","journal-title":"Lancet"},{"key":"10.1111\/tbj.12045-BIB0011|tbj12045-cit-0011","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1200\/JCO.2008.20.5179","article-title":"American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction","volume":"27","author":"Visvanathan","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1111\/tbj.12045-BIB0012|tbj12045-cit-0012","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","article-title":"NCIC CTG MAP.3 Study investigators. Exemestane for breast-cancer prevention in postmenopausal women","volume":"364","author":"Goss","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/tbj.12045-BIB0013|tbj12045-cit-0013","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0140-6736(01)06039-1","article-title":"Uptake of screening and prevention in women at very high risk of breast cancer","volume":"358","author":"Evans","year":"2001","journal-title":"Lancet"},{"key":"10.1111\/tbj.12045-BIB0014|tbj12045-cit-0014","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1200\/JCO.2007.13.6739","article-title":"Psychological and clinical factors implicated in decision making about a trial of low-dose tamoxifen in hormone replacement therapy users","volume":"26","author":"Rondanina","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1111\/tbj.12045-BIB0015|tbj12045-cit-0015","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/1097-0142(20010815)92:4<959::AID-CNCR1406>3.0.CO;2-V","article-title":"Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: differences among English, French, and Canadian women","volume":"92","author":"Julian-Reynier","year":"2001","journal-title":"Cancer"},{"key":"10.1111\/tbj.12045-BIB0016|tbj12045-cit-0016","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s10434-001-0580-9","article-title":"Patient reluctance toward tamoxifen use for breast cancer primary prevention","volume":"8","author":"Port","year":"2001","journal-title":"Ann Surg Oncol"},{"key":"10.1111\/tbj.12045-BIB0017|tbj12045-cit-0017","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/1099-1611(200005\/06)9:3<193::AID-PON454>3.0.CO;2-P","article-title":"Factors implicated in the decision whether or not to join the tamoxifen trial in women at high familial risk of breast cancer","volume":"9","author":"Lovegrove","year":"2000","journal-title":"Psycho-Oncology"},{"key":"10.1111\/tbj.12045-BIB0018|tbj12045-cit-0018","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0140-6736(98)85002-2","article-title":"Is tamoxifen effective in prevention of breast cancer?","volume":"352","author":"Pritchard","year":"1998","journal-title":"Lancet"},{"key":"10.1111\/tbj.12045-BIB0019|tbj12045-cit-0019","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12282-007-0006-z","article-title":"Chemoprevention of breast cancer","volume":"15","author":"Cuzick","year":"2008","journal-title":"Breast Cancer"},{"key":"10.1111\/tbj.12045-BIB0020|tbj12045-cit-0020","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1586\/14737140.8.9.1377","article-title":"IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole","volume":"8","author":"Cuzick","year":"2008","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1111\/tbj.12045-BIB0021|tbj12045-cit-0021","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/1471-2407-6-210","article-title":"Breast cancer screening in women at increased risk according to different family histories: an update of the Modena Study Group experience","volume":"6","author":"Cortesi","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1111\/tbj.12045-BIB0022|tbj12045-cit-0022","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/pon.547","article-title":"Chemoprevention of breast cancer with selective estrogen receptor modulators: views from broadly diverse focus groups of women with elevated risk for breast cancer","volume":"10","author":"Cyrus-Davis","year":"2001","journal-title":"Psycho-oncology"},{"key":"10.1111\/tbj.12045-BIB0023|tbj12045-cit-0023","first-page":"624","article-title":"Women's views on chemoprevention of breast cancer. Qualitative study","volume":"52","author":"Heisey","year":"2006","journal-title":"Can Fam Physician"},{"key":"10.1111\/tbj.12045-BIB0024|tbj12045-cit-0024","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1200\/JCO.2001.19.7.1885","article-title":"Tamoxifen for the prevention of breast cancer: psychosocial impact on women participanting in two randomized controlled trials","volume":"19","author":"Fallowfield","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1111\/tbj.12045-BIB0025|tbj12045-cit-0025","doi-asserted-by":"crossref","first-page":"4951","DOI":"10.1200\/JCO.2004.05.192","article-title":"Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors","volume":"22","author":"Bober","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1111\/tbj.12045-BIB0026|tbj12045-cit-0026","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1075-122X.2006.00295.x","article-title":"Predicting Compliance in a Breast Cancer Prevention Trial","volume":"12","author":"Maurice","year":"2006","journal-title":"Breast J"},{"key":"10.1111\/tbj.12045-BIB0027|tbj12045-cit-0027","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1200\/JCO.1999.17.9.2659","article-title":"Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"17","author":"Day","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1111\/tbj.12045-BIB0028|tbj12045-cit-0028","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1001\/jama.295.23.joc60075","article-title":"Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention the NSABP Study of tamoxifen and raloxifene (STAR) P-2 Trial","volume":"295","author":"Land","year":"2006","journal-title":"JAMA"},{"key":"10.1111\/tbj.12045-BIB0029|tbj12045-cit-0029","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1158\/1940-6207.CAPR-10-0096","article-title":"Long-term follow-up in cancer prevention trials (It ain't over \u2018til it's over)","volume":"3","author":"Cuzick","year":"2010","journal-title":"Cancer Prev Res (Phila)"}],"container-title":["The Breast Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftbj.12045","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/tbj.12045\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:25:54Z","timestamp":1643351154000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tbj.12045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,17]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"URL":"https:\/\/doi.org\/10.1111\/tbj.12045","relation":{},"ISSN":["1075-122X"],"issn-type":[{"type":"print","value":"1075-122X"}],"subject":[],"published":{"date-parts":[[2012,12,17]]}}}